T cells are implicated in the pathogenesis of many inflammatory diseases. To fully activate T cells, both TCR and costimulatory molecule delivered signals are required (Lanzavecchia and Sallusto, 2000). Costimulation blockade targeting various costimulatory molecules seems to be an attractive therapeutic approach for the treatment of T cell-dependent autoimmune diseases. However, these strategies appear to be prophylactic rather than therapeutic, since naive T cell activation are more dependent on costimulatory signaling while the function of preexisting autoreactive T cells are less costimulation-dependent. Another shortcoming of this approach is its requirement of repeated long-lasting treatments, which is costly. Promisingly, recent studies showed that costimulatory agonists of CD137 could prevent and have therapeutic effects on CD4+ T cell-mediated organ-specific autoimmune disease such as experimental autoimmune encephalomyelitis (EAE) and experimental autoimmune uveitis (EAU) (Shao et al., 2005; Sun et al., 2002b), and both CD4+ T cell and autoantibody-involved systemic autoimmune diseases such as systemic lupus erythematosus (SLE), collagen type II-induced arthritis (CIA) and chronic graft-versus-host disease (cGVHD) (Foell et al., 2003, 2004; Kim et al., 2005; Seo et al., 2004; Sun et al., 2002a).
Was this article helpful?
Thank you for deciding to learn more about the disorder, Osteoarthritis. Inside these pages, you will learn what it is, who is most at risk for developing it, what causes it, and some treatment plans to help those that do have it feel better. While there is no definitive “cure” for Osteoarthritis, there are ways in which individuals can improve their quality of life and change the discomfort level to one that can be tolerated on a daily basis.